GLP-1 / GIP / glucagon triple receptor agonist

Retatrutide

LY3437943

Investigational

Retatrutide is an investigational triple GIP / GLP-1 / glucagon receptor agonist under clinical development for obesity and metabolic disease. Investigational; not approved for marketing. Supported through CDMO development and active-ingredient supply.

Specification
CAS number2381089-83-2
Purity≥ 98%
AppearanceWhite to off-white powder
Storage-20 °C ± 5 °C
SolubilityWater / DMSO

Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied; availability is subject to regulatory approval in the buyer's jurisdiction.